Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

Autocrine Adenosine regulates tumor polyfunctional CD73+CD4+ effector T cells devoid of immune checkpoints.

Gourdin N, Bossennec M, Rodriguez C, Vigano S, Machon C, Jandus C, Bauché D, Faget J, Durand I, Chopin N, Tredan O, Marie JC, Dubois B, Guitton J, Romero P, Caux C, Ménétrier-Caux C.

Cancer Res. 2018 Mar 20. pii: canres.2405.2017. doi: 10.1158/0008-5472.CAN-17-2405. [Epub ahead of print]

PMID:
29559470
2.

Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.

Small M, Treilleux I, Couillault C, Pissaloux D, Picard G, Paindavoine S, Attignon V, Wang Q, Rogemond V, Lay S, Ray-Coquard I, Pfisterer J, Joly F, Du Bois A, Psimaras D, Bendriss-Vermare N, Caux C, Dubois B, Honnorat J, Desestret V.

Acta Neuropathol. 2018 Apr;135(4):569-579. doi: 10.1007/s00401-017-1802-y. Epub 2018 Jan 3.

PMID:
29299667
3.

[Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer].

Vignot S, André T, Caux C, Bouleuc C, Evrard S, Gonçalves A, Lacroix M, Magné N, Massard C, Mazeron JJ, Orbach D, Rodrigues M, Thariat J, Wislez M, L'Allemain G, Bay JO.

Bull Cancer. 2018 Jan;105(1):6-14. doi: 10.1016/j.bulcan.2017.11.006. Review. French.

PMID:
29269176
4.

Consent to care of persons with intellectual disability in Quebec: from vulnerability to capability.

Caux C, Lecomte J.

Salud Publica Mex. 2017 Jul-Aug;59(4):462-467. doi: 10.21149/8206.

5.

BAD-LAMP controls TLR9 trafficking and signalling in human plasmacytoid dendritic cells.

Combes A, Camosseto V, N'Guessan P, Argüello RJ, Mussard J, Caux C, Bendriss-Vermare N, Pierre P, Gatti E.

Nat Commun. 2017 Oct 13;8(1):913. doi: 10.1038/s41467-017-00695-1.

6.

Emerging Role of the Unfolded Protein Response in Tumor Immunosurveillance.

Vanacker H, Vetters J, Moudombi L, Caux C, Janssens S, Michallet MC.

Trends Cancer. 2017 Jul;3(7):491-505. doi: 10.1016/j.trecan.2017.05.005. Epub 2017 Jul 6. Review.

PMID:
28718404
7.

The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.

Foy JP, Bertolus C, Michallet MC, Deneuve S, Incitti R, Bendriss-Vermare N, Albaret MA, Ortiz-Cuaran S, Thomas E, Colombe A, Py C, Gadot N, Michot JP, Fayette J, Viari A, Van den Eynde B, Goudot P, Devouassoux-Shisheboran M, Puisieux A, Caux C, Zrounba P, Lantuejoul S, Saintigny P.

Ann Oncol. 2017 Aug 1;28(8):1934-1941. doi: 10.1093/annonc/mdx210.

8.

Pattern recognition receptors: immune targets to enhance cancer immunotherapy.

Shekarian T, Valsesia-Wittmann S, Brody J, Michallet MC, Depil S, Caux C, Marabelle A.

Ann Oncol. 2017 Aug 1;28(8):1756-1766. doi: 10.1093/annonc/mdx179.

PMID:
28444111
9.

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Trédan O, Ménétrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, E Heudel P, Cassier P, Chabaud S, Croughs T, Dupont P, C Cadore A, Clapisson G, Delgado A, Bardin-Dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY, Caux C.

Ann Oncol. 2018 Feb 1;29(2):523. doi: 10.1093/annonc/mdx058. No abstract available.

PMID:
28368453
10.

Description of the immune microenvironment of chondrosarcoma and contribution to progression.

Simard FA, Richert I, Vandermoeten A, Decouvelaere AV, Michot JP, Caux C, Blay JY, Dutour A.

Oncoimmunology. 2016 Dec 7;6(2):e1265716. doi: 10.1080/2162402X.2016.1265716. eCollection 2017.

11.

A Milestone Review on How Macrophages Affect Tumor Growth.

Caux C, Ramos RN, Prendergast GC, Bendriss-Vermare N, Ménétrier-Caux C.

Cancer Res. 2016 Nov 15;76(22):6439-6442. doi: 10.1158/0008-5472.CAN-16-2631. No abstract available.

12.

Les entérobactéries productrices de carbapénémases.

Boivin S, Caux C, Soucy C, Allard A.

Perspect Infirm. 2016 Nov-Dec;13(5):53-56. Review. French. No abstract available.

PMID:
29381281
13.

Ethical competence: An integrative review.

Lechasseur K, Caux C, Dollé S, Legault A.

Nurs Ethics. 2016 Sep 30. pii: 0969733016667773. [Epub ahead of print]

PMID:
27694548
14.

TLR9 re-expression in cancer cells extends the S-phase and stabilizes p16(INK4a) protein expression.

Parroche P, Roblot G, Le Calvez-Kelm F, Tout I, Marotel M, Malfroy M, Durand G, McKay J, Ainouze M, Carreira C, Allatif O, Traverse-Glehen A, Mendiola M, Pozo-Kreilinger JJ, Caux C, Tommasino M, Goutagny N, Hasan UA.

Oncogenesis. 2016 Jul 25;5(7):e244. doi: 10.1038/oncsis.2016.49.

15.

Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy.

Le KS, Thibult ML, Just-Landi S, Pastor S, Gondois-Rey F, Granjeaud S, Broussais F, Bouabdallah R, Colisson R, Caux C, Ménétrier-Caux C, Leroux D, Xerri L, Olive D.

Cancer Res. 2016 Aug 15;76(16):4648-60. doi: 10.1158/0008-5472.CAN-15-0589. Epub 2016 May 31.

16.

Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay.

Verronèse E, Delgado A, Valladeau-Guilemond J, Garin G, Guillemaut S, Tredan O, Ray-Coquard I, Bachelot T, N'Kodia A, Bardin-Dit-Courageot C, Rigal C, Pérol D, Caux C, Ménétrier-Caux C.

Oncoimmunology. 2015 Nov 10;5(3):e1100791. eCollection 2016 Mar.

17.

A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage.

Dezutter-Dambuyant C, Durand I, Alberti L, Bendriss-Vermare N, Valladeau-Guilemond J, Duc A, Magron A, Morel AP, Sisirak V, Rodriguez C, Cox D, Olive D, Caux C.

Oncoimmunology. 2015 Oct 29;5(3):e1091146. eCollection 2016 Mar.

18.

TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway.

Viel S, Marçais A, Guimaraes FS, Loftus R, Rabilloud J, Grau M, Degouve S, Djebali S, Sanlaville A, Charrier E, Bienvenu J, Marie JC, Caux C, Marvel J, Town L, Huntington ND, Bartholin L, Finlay D, Smyth MJ, Walzer T.

Sci Signal. 2016 Feb 16;9(415):ra19. doi: 10.1126/scisignal.aad1884.

PMID:
26884601
19.

In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer.

Clémenceau B, Valsesia-Wittmann S, Jallas AC, Vivien R, Rousseau R, Marabelle A, Caux C, Vié H.

J Immunol Res. 2015;2015:482089. doi: 10.1155/2015/482089. Epub 2015 Nov 17.

20.

[A multidisciplinary approach to cardiac rehabilitation].

Barbet R, Caux C, Brysse L, Foy M, Cardon C.

Soins. 2015 Mar;(793):52-6. French.

PMID:
26040143
21.

Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes.

Ghirelli C, Reyal F, Jeanmougin M, Zollinger R, Sirven P, Michea P, Caux C, Bendriss-Vermare N, Donnadieu MH, Caly M, Fourchotte V, Vincent-Salomon A, Sigal-Zafrani B, Sastre-Garau X, Soumelis V.

Cancer Res. 2015 Jul 15;75(14):2775-87. doi: 10.1158/0008-5472.CAN-14-2386. Epub 2015 May 14.

22.

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Trédan O, Ménétrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, Heudel PE, Cassier P, Chabaud S, Croughs T, Dupont P, Cadore AC, Clapisson G, Delgado A, Bardin-dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY, Caux C.

Ann Oncol. 2015 Jul;26(7):1353-62. doi: 10.1093/annonc/mdv173. Epub 2015 Apr 7.

PMID:
25851629
23.

PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulator-dependent autoimmunity.

Mathieu AL, Verronese E, Rice GI, Fouyssac F, Bertrand Y, Picard C, Chansel M, Walter JE, Notarangelo LD, Butte MJ, Nadeau KC, Csomos K, Chen DJ, Chen K, Delgado A, Rigal C, Bardin C, Schuetz C, Moshous D, Reumaux H, Plenat F, Phan A, Zabot MT, Balme B, Viel S, Bienvenu J, Cochat P, van der Burg M, Caux C, Kemp EH, Rouvet I, Malcus C, Méritet JF, Lim A, Crow YJ, Fabien N, Ménétrier-Caux C, De Villartay JP, Walzer T, Belot A.

J Allergy Clin Immunol. 2015 Jun;135(6):1578-88.e5. doi: 10.1016/j.jaci.2015.01.040. Epub 2015 Apr 2.

24.

Paradigm shift in oncology: targeting the immune system rather than cancer cells.

Shekarian T, Valsesia-Wittmann S, Caux C, Marabelle A.

Mutagenesis. 2015 Mar;30(2):205-11. doi: 10.1093/mutage/geu073. Review.

PMID:
25688113
25.

Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response.

Chapellier M, Bachelard-Cascales E, Schmidt X, Clément F, Treilleux I, Delay E, Jammot A, Ménétrier-Caux C, Pochon G, Besançon R, Voeltzel T, Caron de Fromentel C, Caux C, Blay JY, Iggo R, Maguer-Satta V.

Stem Cell Reports. 2015 Feb 10;4(2):239-54. doi: 10.1016/j.stemcr.2014.12.007. Epub 2015 Jan 15.

26.

TLR9 transcriptional regulation in response to double-stranded DNA viruses.

Zannetti C, Parroche P, Panaye M, Roblot G, Gruffat H, Manet E, Debaud AL, Plumas J, Vey N, Caux C, Bendriss-Vermare N, Hasan UA.

J Immunol. 2014 Oct 1;193(7):3398-408. doi: 10.4049/jimmunol.1400249. Epub 2014 Sep 5.

27.

[Moral distress of nurses: literature review].

Poisson C, Alderson M, Caux C, Brault I.

Rech Soins Infirm. 2014 Jun;(117):65-74. Review. French.

PMID:
25080625
28.

Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.

Deauvieau F, Ollion V, Doffin AC, Achard C, Fonteneau JF, Verronese E, Durand I, Ghittoni R, Marvel J, Dezutter-Dambuyant C, Walzer T, Vie H, Perrot I, Goutagny N, Caux C, Valladeau-Guilemond J.

Int J Cancer. 2015 Mar 1;136(5):1085-94. doi: 10.1002/ijc.29087. Epub 2014 Aug 6.

29.

Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells.

Balan S, Ollion V, Colletti N, Chelbi R, Montanana-Sanchis F, Liu H, Vu Manh TP, Sanchez C, Savoret J, Perrot I, Doffin AC, Fossum E, Bechlian D, Chabannon C, Bogen B, Asselin-Paturel C, Shaw M, Soos T, Caux C, Valladeau-Guilemond J, Dalod M.

J Immunol. 2014 Aug 15;193(4):1622-35. doi: 10.4049/jimmunol.1401243. Epub 2014 Jul 9.

30.

Intratumoral immunization: a new paradigm for cancer therapy.

Marabelle A, Kohrt H, Caux C, Levy R.

Clin Cancer Res. 2014 Apr 1;20(7):1747-56. doi: 10.1158/1078-0432.CCR-13-2116.

31.

[Spontaneous regression of breast cancer after biopsy. About two cases].

Maillet L, Chopin N, Treilleux I, Bachelot T, Tredan O, Faure C, Caux C, Beurrier F.

Gynecol Obstet Fertil. 2014 Apr;42(4):269-72. doi: 10.1016/j.gyobfe.2013.08.017. Epub 2014 Jan 3. French.

PMID:
24394327
32.

[Positive deviance: concept analysis using the evolutionary approach of Rodgers].

Létourneau J, Alderson M, Caux C, Richard L.

Rech Soins Infirm. 2013 Jun;(113):19-33. Review. French.

PMID:
23923735
33.

ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4+ T cells by plasmacytoid dendritic cells.

Faget J, Sisirak V, Blay JY, Caux C, Bendriss-Vermare N, Ménétrier-Caux C.

Oncoimmunology. 2013 Mar 1;2(3):e23185.

34.

Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment.

Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, Dubois B, Treilleux I, Marvel J, Vlach J, Blay JY, Bendriss-Vermare N, Caux C, Puisieux I, Goutagny N.

Cancer Res. 2013 Aug 1;73(15):4629-40. doi: 10.1158/0008-5472.CAN-12-3058. Epub 2013 May 30.

35.
36.

Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells.

Sisirak V, Vey N, Goutagny N, Renaudineau S, Malfroy M, Thys S, Treilleux I, Labidi-Galy SI, Bachelot T, Dezutter-Dambuyant C, Ménétrier-Caux C, Blay JY, Caux C, Bendriss-Vermare N.

Int J Cancer. 2013 Aug 1;133(3):771-8. doi: 10.1002/ijc.28072. Epub 2013 Mar 8.

37.

Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas.

el Sayadi H, Pissaloux D, Alberti L, Tabone-Eglinger S, Ranchere D, Decouvelaere AV, Tabone E, Ray-Coquard I, Caux C, Fayette J, Blay JY.

Target Oncol. 2013 Dec;8(4):261-9. doi: 10.1007/s11523-012-0249-2. Epub 2013 Jan 25.

PMID:
23354874
38.

Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome.

Trédan O, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-dit-Courageot C, Rigal C, Biota C, Bajard A, Pasqual N, Blay JY, Caux C, Ménétrier-Caux C.

Eur J Cancer. 2013 May;49(7):1673-82. doi: 10.1016/j.ejca.2012.11.028. Epub 2012 Dec 19.

PMID:
23265706
39.

CD4 lymphopenia to identify end-of-life metastatic cancer patients.

Péron J, Cropet C, Tredan O, Bachelot T, Ray-Coquard I, Clapisson G, Chabaud S, Philip I, Borg C, Cassier P, Labidi Galy I, Sebban C, Perol D, Biron P, Caux C, Menetrier-Caux C, Blay JY.

Eur J Cancer. 2013 Mar;49(5):1080-9. doi: 10.1016/j.ejca.2012.11.003. Epub 2012 Dec 13.

PMID:
23246297
40.

Immunobiology. Combined targeted and immunotherapy: the future of personalized medicine.

Marabelle A, Caux C.

Blood. 2012 Nov 29;120(23):4454-5. doi: 10.1182/blood-2012-09-455105.

41.

ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.

Faget J, Bendriss-Vermare N, Gobert M, Durand I, Olive D, Biota C, Bachelot T, Treilleux I, Goddard-Leon S, Lavergne E, Chabaud S, Blay JY, Caux C, Ménétrier-Caux C.

Cancer Res. 2012 Dec 1;72(23):6130-41. doi: 10.1158/0008-5472.CAN-12-2409. Epub 2012 Oct 1.

42.

Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment.

Ménétrier-Caux C, Faget J, Biota C, Gobert M, Blay JY, Caux C.

Oncoimmunology. 2012 Aug 1;1(5):759-761.

43.

Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression.

Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Renaudineau S, Poyet G, Labidi-Galy SI, Goddard-Leon S, Durand I, Le Mercier I, Bajard A, Bachelot T, Puisieux A, Puisieux I, Blay JY, Ménétrier-Caux C, Caux C, Bendriss-Vermare N.

Cancer Res. 2012 Oct 15;72(20):5188-97. doi: 10.1158/0008-5472.CAN-11-3468. Epub 2012 Jul 25.

44.

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients.

Manuel M, Tredan O, Bachelot T, Clapisson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, Perol D, Chabaud S, Ray-Coquard I, Labidi-Galy I, Heudel P, Pierga JY, Caux C, Blay JY, Pasqual N, Ménétrier-Caux C.

Oncoimmunology. 2012 Jul 1;1(4):432-440.

45.

Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis.

Labidi-Galy SI, Treilleux I, Goddard-Leon S, Combes JD, Blay JY, Ray-Coquard I, Caux C, Bendriss-Vermare N.

Oncoimmunology. 2012 May 1;1(3):380-382.

46.

[PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved].

Ray-Coquard I, Chauvin F, Leblanc E, Caux C, Hoarau H, Bonnetain F, Christophe V, Sastre-Garau X, Lazennec G, Poulain L, Haie-Meder C, Pujade-Lauraine E, Salzet M, Deutsch E, Devouassoux M, Penault Llorca F, Lecuru F, Taieb S, Arveux P, Theillet C, Joly F.

Bull Cancer. 2012 Apr 1;99(4):479-98. doi: 10.1684/bdc.2012.1558. Review. French.

47.

Targeting pattern recognition receptors in cancer immunotherapy.

Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C.

Target Oncol. 2012 Mar;7(1):29-54. doi: 10.1007/s11523-012-0213-1. Epub 2012 Mar 8. Review.

PMID:
22399234
48.

Recent successes of cancer immunotherapy: a new dimension in personalized medicine?

Caux C, Zitvogel L.

Target Oncol. 2012 Mar;7(1):1-2. doi: 10.1007/s11523-012-0211-3. Epub 2012 Feb 15. No abstract available.

PMID:
22350488
49.

Targeting regulatory T cells.

Ménétrier-Caux C, Curiel T, Faget J, Manuel M, Caux C, Zou W.

Target Oncol. 2012 Mar;7(1):15-28. doi: 10.1007/s11523-012-0208-y. Epub 2012 Feb 12. Review.

PMID:
22327882
50.

CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues.

Sisirak V, Vey N, Vanbervliet B, Duhen T, Puisieux I, Homey B, Bowman EP, Trinchieri G, Dubois B, Kaiserlian D, Lira SA, Puisieux A, Blay JY, Caux C, Bendriss-Vermare N.

Blood. 2011 Nov 10;118(19):5130-40. doi: 10.1182/blood-2010-07-295626. Epub 2011 Sep 21.

Supplemental Content

Support Center